Figure 3.

Probability that agomelatine is cost-effective against branded comparators at alternative monetary values of a quality-adjusted-life-year, when both direct health care costs and indirect costs were considered in the analysis.

Maniadakis et al. BMC Health Services Research 2013 13:173   doi:10.1186/1472-6963-13-173
Download authors' original image